Phase II Study of Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia.

Trial Profile

Phase II Study of Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Jun 2015 Planned End Date changed from 1 Jul 2014 to 1 Jul 2018 as reported by ClinicalTrials.gov record.
    • 16 Jun 2015 Planned primary completion date changed from 1 Jul 2014 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
    • 13 Jun 2014 Planned End Date changed from 1 Dec 2013 to 1 Jul 2014 as repoted by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top